The kappa opioid receptor (KOR) has been implicated in the etiology of fear, threat, and anhedonia in animal models of human depression psychopathology. Herein, we propose to study the KOR in vivo using positron emission tomography, and we will also measure the activity of the HPA-axis in all study participants. We propose to recruit up to N=50 medication-free individuals using a transdiagnostic approach, measure their KOR-selective radioligand [11C]LY2795050 volumes of distribution (VT), an equivalent of KOR availability using PET and study the role of the KOR in mediating the quality and severity of the depressive phenotype. This application is in response to the RDoC initiative of NIMH to clarify the role of the KOR in mediating fear, threat, and reward responsiveness.

Public Health Relevance

Better understanding of the interactive effects of the kappa opioid receptor (KOR) and glucocorticoid signaling has the potential to provide not only improved understanding of the neurobiology of aspects of the depressive phenotype, i.e. threat, fear and anhedonia, but may also lead to improving interventions and services for depressed individuals. We propose to recruit N=50 medication-free individuals across different diagnostic entities and with differing symptom severity and quality of the depressive syndrome, measure their [11C]LY2795050 volumes of distribution (VT), an equivalent of KOR availability using positron emission tomography (PET) and determine the role of the KOR and glucocorticoid signaling in mediating the heterogeneous components of the depressive phenotype.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Research Project (R01)
Project #
Application #
Study Section
Pathophysiological Basis of Mental Disorders and Addictions Study Section (PMDA)
Program Officer
Rumsey, Judith M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Schools of Medicine
New York
United States
Zip Code
Cai, Zhengxin; Li, Songye; Pracitto, Richard et al. (2017) Fluorine-18-Labeled Antagonist for PET Imaging of Kappa Opioid Receptors. ACS Chem Neurosci 8:12-16
Neumeister, Alexander; Seidel, Jordan; Ragen, Benjamin J et al. (2015) Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder. Psychoneuroendocrinology 51:577-84
Ragen, Benjamin J; Seidel, Jordan; Chollak, Christine et al. (2015) Investigational drugs under development for the treatment of PTSD. Expert Opin Investig Drugs 24:659-72
Pietrzak, Robert H; Naganawa, Mika; Huang, Yiyun et al. (2014) Association of in vivo ?-opioid receptor availability and the transdiagnostic dimensional expression of trauma-related psychopathology. JAMA Psychiatry 71:1262-70
Horn, Charlotte A C; Pietrzak, Robert H; Corsi-Travali, Stefani et al. (2014) Linking plasma cortisol levels to phenotypic heterogeneity of posttraumatic stress symptomatology. Psychoneuroendocrinology 39:88-93
Pietrzak, Robert H; Huang, Yiyun; Corsi-Travali, Stefani et al. (2014) Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Neuropsychopharmacology 39:2519-28
Pietrzak, Robert H; Gallezot, Jean-Dominique; Ding, Yu-Shin et al. (2013) Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus. JAMA Psychiatry 70:1199-205